Drug Trial Radar · NCT05428943
OPT101 in Type 1 Diabetes Patients
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 27, 2022
Primary completion
Feb 21, 2024
Study completion Feb 21, 2024
Sponsor
- Lead sponsor
- Op-T LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.
Conditions
- Diabetes Mellitus, Type 1
Interventions
OPT101Drug
15-mer peptide derived from the sequence of mouse CD154.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment-related AE's as Assessed by CTCAE v4.0Time frame: 42 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Diablo Clinical Research Center
Walnut Creek, California
Rainier Clinical Research Center
Renton, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.